MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. It also provides over-the counter and food supplement products under the Neurobion, Bion3, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Vivera/Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of biotechnological drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, coatings, printing technology, paints, plastics, and cosmetics. It has strategic alliances with Pfizer Inc. and Baylor College of Medicine; an agreement with Bristol-Myers Squibb Company for the co-commercialization of Glucophage, an antidiabetic agent in China; a strategic collaboration and license agreement with Intrexon Corporation to develop and commercialize chimeric antigen receptor T-cell cancer therapies; and collaborations with F-star Delta Ltd, as well as a strategic collaboration agreement with Alibaba Health to provide Chinese patients and their families with patient-centric healthcare services. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
Industry, Sector and Symbol
Stock Exchange FRA
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolFRA:MRK
CUSIPN/A
Phone+49-6151-720
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares129,240,000
Market Cap$10,070.00
Merck KGaA (FRA:MRK) Frequently Asked Questions
What is Merck KGaA's stock symbol?
Merck KGaA trades on the FRA under the ticker symbol "MRK."
What price target have analysts set for MRK?
23 Wall Street analysts have issued 1-year price objectives for Merck KGaA's shares. Their forecasts range from €70.00 to €125.00. On average, they expect Merck KGaA's share price to reach €98.77 in the next year. This suggests a possible upside of 15.5% from the stock's current price. View Analyst Ratings for Merck KGaA.
What is the consensus analysts' recommendation for Merck KGaA?
23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 1 sell rating, 10 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
Who are some of Merck KGaA's key competitors?
Some companies that are related to Merck KGaA include MERCK KGAA/S (MKKGY), Valeant Pharmaceuticals Intl (VRX), Canopy Growth (WEED), Aurora Cannabis (ACB), STADA Arzneimittel (SAZ), Hikma Pharmaceuticals (HKMPY), Hikma Pharmaceuticals (HIK), Aphria (APH), MedReleaf (LEAF), Knight Therapeutics (KHTRF), Hydropothecary (THCX), OrganiGram (OGI), Supreme Cannabis (FIRE), Weed (BUDZ) and OrganiGram (OGRMF).
Who are Merck KGaA's key executives?
Merck KGaA's management team includes the folowing people:
- Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 61)
- Dr. Marcus Kuhnert, Chief Financial Officer & Member of Exec. Board (Age 50)
- Dr. Walter Galinat, Member of Exec. Board (Age 62)
- Dr. Kai Beckmann, Member of the Exec. Board & CEO of Performance Materials (Age 53)
- Dr. Udit Batra, Member of Exec. Board & Chief Exec. Officer of Life Sciences (Age 47)
Has Merck KGaA been receiving favorable news coverage?
News stories about MRK stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Merck KGaA earned a news impact score of 0.22 on Accern's scale. They also assigned news articles about the healthcare company an impact score of 45.87 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
What is Merck KGaA's stock price today?
One share of MRK stock can currently be purchased for approximately €85.50.
How big of a company is Merck KGaA?
Merck KGaA has a market capitalization of $10.07 billion.
How can I contact Merck KGaA?
Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.
MarketBeat Community Rating for Merck KGaA (FRA MRK)
MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
